Combination therapy for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial combines an immunotherapy (Envafolimab), a targeted therapy (Suvemcitug), and a special chemotherapy infusion that goes directly into the liver (HAIC) to try to shrink or control advanced liver cancer that can't be removed by surgery. The goal is to help convert the tumor to a state where it might be operable, and to improve long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need a diagnosis of hepatocellular carcinoma (the most common type of liver cancer) that is stage III or IV and cannot be removed by surgery.
- Your liver function must be adequate (a Child-Pugh score of 7 points or less).
- You cannot have had any prior treatment for this cancer, including immunotherapy, targeted therapy, or anti-cancer herbal/TCM medicines.
- You need a tumor that can be measured on a scan (at least 1 cm across for a non-lymph node tumor, or 1.5 cm for a lymph node).
- Your overall health and organ function (blood counts, liver, kidney, and clotting) must be within trial limits.
- You must not have other active cancers, serious autoimmune disease, bleeding risks, or unstable heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Potentially Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.